[Federal Register Volume 77, Number 49 (Tuesday, March 13, 2012)]
[Notices]
[Pages 14769-14770]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2012-5943]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Office of the Secretary


Meeting of the Uniform Formulary Beneficiary Advisory Panel

AGENCY: Department of Defense, Assistant Secretary of Defense (Health 
Affairs).

ACTION: Notice of meeting.

-----------------------------------------------------------------------

SUMMARY: Under the provisions of the Federal Advisory Committee Act of 
1972 (Title 5, United States Code (U.S.C.), Appendix, as amended) and 
the Government in the Sunshine Act of 1976 (Title 5, U.S.C., Section 
552b, as amended) the Department of Defense (DoD) announces the 
following Federal Advisory Committee meeting of the Uniform Formulary 
Beneficiary Advisory Panel (hereafter referred to as the Panel).

DATES: April 5, 2012, from 9 a.m. to 1 p.m.

ADDRESSES: Naval Heritage Center Theater, 701 Pennsylvania Avenue NW., 
Washington, DC 20004.

FOR FURTHER INFORMATION CONTACT: CDR Joseph Lawrence, Designated 
Federal Officer (DFO), Uniform Formulary Beneficiary Advisory Panel, 
4130 Stanley Road, Suite 208, Building 1000, San Antonio, TX 78234-
6012. Telephone: (210) 295-1271 Fax: (210) 295-2789. Email Address: 
<a href="/cdn-cgi/l/email-protection#541635242631252131272027142039357a3b27307a393d38"><span class="__cf_email__" data-cfemail="0e4c6f7e7c6b7f7b6b7d7a7d4e7a636f20617d6a20636762">[email protected]</span></a>.

SUPPLEMENTARY INFORMATION:
    Purpose of Meeting: The Panel will review and comment on 
recommendations made to the Director of TRICARE Management Activity, by 
the Pharmacy and Therapeutics Committee, regarding the Uniform 
Formulary.

Meeting Agenda

1. Sign-In.
2. Welcome and Opening Remarks.
3. Public Citizen Comments.
4. Scheduled Therapeutic Class Reviews (Comments will follow each 
agenda item).
    a. Attention Deficit Hyperactivity Disorder-Narcolepsy Agents.
    b. Anti-Platelet Hemorhelogic Agents.
    c. Diabetes Non-Insulin: Dipeptidyl Peptidase--4(DPP-4) Inhibitors.
    d. Designated Newly Approved Drugs in Already-Reviewed Classes.
    e. Pertinent Utilization Management Issues.
5. Panel Discussions and Vote.

    Meeting Accessibility: Pursuant to 5 U.S.C. 552b, as amended, and 
Title 41, Code of Federal Regulations (CFR), 102-3.140 through 102-
3.165, and the availability of space, this meeting is open to the 
public. Seating is limited and will be provided only to the first 220 
people signing-in. All persons must sign-in legibly.
    Administrative Work Meeting: Prior to the public meeting, the Panel 
will conduct an Administrative Work Meeting from 8 a.m. to 9 a.m. to 
discuss administrative matters of the Panel. The Administrative Work 
Meeting will be held at the Naval Heritage Center, 701 Pennsylvania 
Avenue NW., Washington, DC 20004. Pursuant to 41 CFR 102-3.160, the 
Administrative Work Meeting will be closed to the public.
    Written Statements: Pursuant to 41 CFR 102-3.105(j) and 102-3.140, 
the public or interested organizations may submit written statements to 
the membership of the Panel at any time or in response to the stated 
agenda of a planned meeting. Written statements should be submitted to 
the Panel's DFO. The DFO's contact information can be obtained from the 
General Services Administration's Federal Advisory Committee Act 
Database at https://www.fido.gov/facadatabase/public.asp.
    Written statements that do not pertain to the scheduled meeting of 
the Panel may be submitted at any time. However, if individual comments 
pertain to a specific topic being discussed at a planned meeting, then 
these statements must be submitted no later than 5 business days prior 
to the meeting in question. The DFO will review all submitted written 
statements and provide copies to all the committee members.
    Public Comments: In addition to written statements, the Panel will 
set aside 1 hour for individuals or interested groups to address the 
Panel. To ensure consideration of their comments, individuals and 
interested groups should submit written statements as outlined in this 
notice; but if they still want to address the Panel, then they will be 
afforded the opportunity to register to address the Panel. The Panel's 
DFO will have a ``Sign-Up Roster'' available at the Panel meeting for 
registration on a first-come, first-serve basis. Those wishing to 
address the Panel will be given no more than 5 minutes to present their 
comments, and at the end of the 1 hour time period, no further public 
comments will be accepted. Anyone who signs-up to address the Panel, 
but is unable to do so due to the time limitation, may submit their 
comments in writing; however, they must understand that their written 
comments may not be reviewed prior to the Panel's deliberation.

[[Page 14770]]

    To ensure timeliness of comments for the official record, the Panel 
encourages that individuals and interested groups consider submitting 
written statements instead of addressing the Panel.

    Dated: March 7, 2012.
Aaron Siegel,
Alternate OSD Federal Register Liaison Officer, Department of Defense.
[FR Doc. 2012-5943 Filed 3-12-12; 8:45 am]
BILLING CODE 5001-06-P


</pre><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script></body>
</html>